Skip to content
Research Article Open access CC BY 4.0

Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices Analysis Modeling

Xiao X. Zhu, Yan Li, Xuan R. Zhang, Lun Yuan, Pei H. Luo, X. Gao, Zhong S. Tan

Journal of Pharmaceutical Research International · pp. 1–17 · Published 16 Nov 2018

10.9734/JPRI/2018/44771

Abstract

Aim: This work aims to understand potential inhibitory structural requirements and identify lead compounds for non-small cell lung cancer through 3D-QSAR pharmacophore-based virtual screening, molecular docking, CoMSIA and CoMFA QSAR modelling. Materials and Methods: QSAR pharmacophore models were developed by HypoGen Module and validated by test data set, Fischer’s randomization and Guner-Henry equation. The well-validated pharmacophore model was employed to perform virtual screening to identify potent hits from ZINC database. The retrieved hits were subsequently subjected to filtering using ADMET descriptors and Lipinski’s Rule of Five. CoMSIA and CoMFA were then utilized to produce QSAR models on phenylpyrimidine derivatives also. Results: Validations on 3D-QSAR pharmacophore model indicate that the enrichment factor is 6.34, GH is 0.517 and a correlation coefficient is 0.83, implying its highly predictive ability. Top three hits: ZINC29356266, ZINC06589615, and ZINC03375633 were identified as promising potent inhibitory candidates with IC50 value of about 0.54 µM and fitness value of about 59.4. Interestingly, the top three hits indicate dual inhibitory activity targeting EGFR and PD-L1 from structure-based docking. Two developed QSAR models from CoMSIA and CoMFA modelling indicate a potential predictive ability (q2=0.67, and 0.71 respectively). The designed compound C indicates a more potential (dual) inhibitory activity (pIC50=7.39) targeting EGFR (fitness=59.78) and CTLA-4 (fitness =47.90). Conclusion: Validations indicate that the developed 3D-QSAR pharmacophore model is highly predictive. Top three hits were identified as promising potent inhibitory candidates and indicated dual inhibitory activity targeting EGFR and PD-L1. The designed compound C indicates a more potential (dual) inhibitory activity targeting EGFR and CTLA‐4. These important 3D-QSAR and molecular docking bioinformatics results achieved from this work should be valuable in designing more promising potent inhibitory candidates and developing novel lead compounds against advanced NSCLC in future.

Bioinformatics molecular docking QSAR pharmacophore comparative molecular similarity indices analysis.

References (30)

  1. 1 Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer [DOI]
  2. 2 Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer [DOI]
  3. 3 PD-1 blockade induces responses by inhibiting adaptive immune resistance [DOI]
  4. 4 Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [DOI]
  5. 5 Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [DOI]
  6. 6 Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers [DOI]
  7. 7 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer [DOI]
  8. 8 Pharmacophore perception, development, and use in drug design
  9. 9 Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 [DOI]
  10. 10 An Introduction To Chemoinformatics [DOI]
  11. 11 Recognizing Pitfalls in Virtual Screening: A Critical Review [DOI]
  12. 12 PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? [DOI]
  13. 13 Synthesis and structure–activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide hydrazone derivatives as potential agents against A549 lung cancer cells [DOI]
  14. 14 PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis [DOI]
  15. 15 The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis [DOI]
  16. 16 Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor [DOI]
  17. 17 PD-L1 Testing in Cancer [DOI]
  18. 18 Immune Checkpoint Modulation for Non–Small Cell Lung Cancer [DOI]
  19. 19 Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters [DOI]
  20. 20 Cu(OTf)2 catalyzed three component reaction: Efficient synthesis of spiro[indoline-3,4′-pyrano[3,2-b]pyran derivatives and their anticancer potency towards A549 human lung cancer cell lines [DOI]
  21. 21 Three Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors. Potential Agents for Prostate Cancer Therapy [DOI]
  22. 22 Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR‐Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway [DOI]
  23. 23 Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies [DOI]
  24. 24 Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo [DOI]
  25. 25 Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials [DOI]
  26. 26 Potential role of immunotherapy in advanced non-small-cell lung cancer [DOI]
  27. 27 Synthesis and antiproliferative activity of benzofuran-based analogs of cercosporamide against non-small cell lung cancer cell lines [DOI]
  28. 28 Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – A systematic review and network meta-analysis of 3024 participants [DOI]
  29. 29 CoMFA 3D-QSAR Analysis of HIV-1 RT Nonnucleoside Inhibitors, TIBO Derivatives Based on Docking Conformation and Alignment [DOI]
  30. 30 Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

59

Page views

0

PDF downloads

22

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.